CAPRICOR THERAPEUTICS INC (CAPR) Stock Price, Forecast & Analysis
USA - NASDAQ:CAPR - US14070B3096 - Common Stock
CAPR Key Statistics, Chart & Performance
The current stock price of CAPR is 6.07 USD. In the past month the price decreased by -17.59%. In the past year, price decreased by -68.12%.
CAPR Latest News, Press Relases and Analysis
CAPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.22 | 387.57B | ||
| AMGN | AMGEN INC | 14.63 | 172.23B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.5 | 104.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.4 | 68.70B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 854.58 | 57.13B | ||
| INSM | INSMED INC | N/A | 39.24B | ||
| NTRA | NATERA INC | N/A | 27.16B | ||
| BIIB | BIOGEN INC | 9.15 | 22.45B | ||
| INCY | INCYTE CORP | 16.4 | 20.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.87 | 20.13B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.73 | 14.81B |
Related stock screener links
About CAPR
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Company Info
CAPRICOR THERAPEUTICS INC
10865 Road to the Cure, Suite 150
San Diego CALIFORNIA 90211 US
CEO: Linda Marban
Employees: 160
Phone: 13103583200
CAPRICOR THERAPEUTICS INC / CAPR FAQ
What does CAPR do?
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Can you provide the latest stock price for CAPRICOR THERAPEUTICS INC?
The current stock price of CAPR is 6.07 USD. The price decreased by -3.34% in the last trading session.
Does CAPR stock pay dividends?
CAPR does not pay a dividend.
How is the ChartMill rating for CAPRICOR THERAPEUTICS INC?
CAPR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of CAPR stock?
CAPRICOR THERAPEUTICS INC (CAPR) has a market capitalization of 277.52M USD. This makes CAPR a Micro Cap stock.
Who owns CAPRICOR THERAPEUTICS INC?
You can find the ownership structure of CAPRICOR THERAPEUTICS INC (CAPR) on the Ownership tab.
What is the Short Interest ratio of CAPRICOR THERAPEUTICS INC (CAPR) stock?
The outstanding short interest for CAPRICOR THERAPEUTICS INC (CAPR) is 32.2% of its float.
CAPR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR is a bad performer in the overall market: 96.27% of all stocks are doing better.
CAPR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CAPR. No worries on liquidiy or solvency for CAPR as it has an excellent financial health rating, but there are worries on the profitability.
CAPR Financial Highlights
Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS decreased by -76.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.39% | ||
| ROE | -66.66% | ||
| Debt/Equity | 0 |
CAPR Forecast & Estimates
16 analysts have analysed CAPR and the average price target is 21.01 USD. This implies a price increase of 246.16% is expected in the next year compared to the current price of 6.07.
For the next year, analysts expect an EPS growth of -85.41% and a revenue growth -92.12% for CAPR